Pipeline - Athenex

Athenex’s clinical pipeline includes small molecule, biologic, and cell therapies for the treatment of cancer.

Program	Drug Candidate	Indication	Pre-Clinical
Src Kinase Inhibition	Klisyri^® (tirbanibulin ointment)	Actinic keratosis	FDA Approved	Phase 3 — FDA Approved
Orascovery	Oral paclitaxel + encequidar	Metastatic breast cancer	RECEIVED CRL FROM FDA	Phase 3 — RECEIVED CRL FROM FDA
Orascovery	Oral paclitaxel + encequidar	Angiosarcoma		Phase 2
Orascovery	Oral paclitaxel + encequidar w/ dostarlimab*	Neoadjuvant breast cancer (I-SPY 2)		Phase 2
Orascovery	Oral paclitaxel + encequidar w/ ramucirumab**	Gastric cancer		Phase 1
Orascovery	Oral paclitaxel + encequidar w/ pembrolizumab	Solid tumors		Phase 1
Orascovery	Oral docetaxel + encequidar	Solid tumors		Phase 1
Orascovery	Oral irinotecan + encequidar	Solid tumors		Phase 1
Orascovery	Oral eribulin + encequidar	Solid tumors		Phase 1
Cell Therapy	TCRT-ESO-A2	Multiple tumors		Phase 1
Cell Therapy	KUR-501 – GD2 autologous CAR-NKT	Neuroblastoma		Phase 1
Cell Therapy	KUR-502 – CD19 allogeneic CAR-NKT	R/R lymphoma and leukemia		Phase 1
Cell Therapy	KUR-503 – GPC3 allogeneic CAR-NKT	Hepatocellular Carcinoma		Pre-Clinical
Arginase Deprivation Therapy	PT01	Multiple tumors		Phase 1

* Collaboration with Quantum Leap Healthcare Collaborative and GlaxoSmithKline
** Collaboration with Eli Lilly and Company, makers of ramucirumab

For more information about our trials, please visit clinicaltrials.gov.